• Statistical Genetics of Complex Diseases
• 38 min
  1. Population genetics considerations

  • Prof. Nan Laird
• 39 min
  2. Gene-by-environment interaction: study designs and analytical methods

  • Prof. L. Adrienne Cupples
• 59 min
  3. Analysis of SNP haplotypes

  • Prof. Lyle Palmer
• 36 min
  4. Statistical issues in epidemiological studies of gene-environment interaction

  • Dr. Peter Kraft
  • Prof. Donna Spiegelman
• Molecular Epidemiology of Pulmonary Diseases
• 57 min
  5. Molecular epidemiology of lung cancer

  • Prof. David Christiani
• 34 min
  6. Ethical issues in molecular epidemiology and studies of gene-environment interactions

  • Dr. Richard Sharp
• Autoimmune Diffuse Connective Tissue Diseases
• 29 min
  7. Environmental scleroderma: the evidence for putative triggers

  • Prof. Maureen Mayes
• Drug-Induced Disease
• 35 min
  8. Drug-induced lupus

  • Prof. Evelyn Hess
• Archived Lectures *These may not cover the latest advances in the field
• 41 min
  9. Biomarkers of exposure

  • Prof. Thomas Smith
• 43 min
  10. GIS and spatial statistics

  • Prof. Louise Ryan
• 47 min
  11. Gene-by-environment interactions in COPD

  • Prof. Edwin Silverman
• 40 min
  12. Occupational and environmental influences on the development and course of lupus

  • Dr. Glinda Cooper
• 54 min
  13. Genetic susceptibility in granulomatous disorders: chronic beryllium disease and sarcoidosis

  • Prof. Lee Newman
• 29 min
  14. Indians, twins and scleroderma: genetic and genomic studies

  • Prof. Frank Arnett
• 27 min
  15. Gene by environment interaction in asthma

  • Prof. Scott Weiss
• 42 min
  16. Molecular epidemiology of lung cancer

  • Prof. David Christiani
• 18 min
  17. Racial and ethnic variation in systemic lupus erythematosus and systemic sclerosis (scleroderma)

  • Dr. Patricia Fraser
• 47 min
  18. Infectious environmental factors and systemic lupus erythematosus

  • Prof. Judith James

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Environmental disease process
3. Occupational disease process
4. Types of biomarkers
5. What do we mean by exposure?
6. Exposure-biomarker dose relationships
7. Toxicokinetics and models
8. Modeling the kinetics: simple model
9. Model results
10. Application of biomarkers: defining biomarker utility
11. Example: gasoline additives
12. Concern: human health risks
13. Purposes of physiologic modeling
14. Internal kinetics of an inhalation exposure
15. PBTK: model structure
16. PBTK: genetic effects on biomarkers
17. Inter-individual variation
18. Differences by route of entry
19. Common biomarkers - different kinetics
20. Human laboratory exposures
21. Subjects for the MTBE study: Larry to the rescue
22. Human exposure study
23. Toxicokinetics: MTBE, blood data
24. Toxicokinetics: TBA metabolite, blood data
25. Toxicokinetic findings
26. MTBE acute effects
27. Study limitations
28. Key points
29. Thank you

Topics Covered

• Biomarkers as indicators of exposure, adverse effects or susceptibility for an individual
• Methods of exposure: inhalation, ingestion or skin absorption
• Toxicokinetics as a guide to understanding biomarker behaviour
• Calibration of biomarkers
• Example of using biomarkers for exposure to MTBE in gasoline
• Using a physiologically based toxicokinetic (PBTK) model of MTBE to estimate tissue and biomarker levels
• Metabolic gene-environment interaction in biomarker production
• Using lab exposures to study biomarkers and the dose-response relationship

Links

Series:

• Gene-Environment Interactions

Categories:

• Clinical Practice

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on June 22, 2016

Financial Disclosures

• Prof. Thomas Smith has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.